Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Current Deferred Revenue (2023 - 2026)

BioAge Labs' Current Deferred Revenue history spans 3 years, with the latest figure at $5.8 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 26.48% to $5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.8 million, a 26.48% decrease, with the full-year FY2025 number at $5.8 million, down 26.48% from a year prior.
  • Current Deferred Revenue hit $5.8 million in Q4 2025 for BioAge Labs, down from $7.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BIOA hit a ceiling of $8.2 million in Q1 2025 and a floor of $3.3 million in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $6.7 million across 3 years, with a median of $7.6 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 136.22% in 2024 and later dropped 26.48% in 2025.
  • Tracing BIOA's Current Deferred Revenue over 3 years: stood at $3.3 million in 2023, then surged by 136.22% to $7.8 million in 2024, then dropped by 26.48% to $5.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BIOA at $5.8 million in Q4 2025, $7.5 million in Q3 2025, and $7.7 million in Q2 2025.